Dutasteride, cantharidin, atopiclair, cetuximab, sirolimus, AC-11 and dimericine reviewed in brief.
Scheinfeld
Noah
N
St. Luke's-Roosevelt Hospital Center, New York, NY, USA.
D000152:Acne Vulgaris / Q000150:complications*; D000505:Alopecia / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001378:Azasteroids / Q000627:therapeutic use*; D002193:Cantharidin / Q000009:adverse effects / Q000627:therapeutic use*; D000068818:Cetuximab; D000068538:Dutasteride; D005260:Female; D006801:Humans; D008297:Male; D008976:Molluscum Contagiosum / Q000188:drug therapy*; D020123:Sirolimus / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001378:Azasteroids; D002193:Cantharidin; D000068538:Dutasteride; D000068818:Cetuximab; D020123:Sirolimus